CG
ACAD icon

Caprock Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Caprock Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,207
Closed -$225K – 495
2020
Q4 		$225K Buy
+4,207
New +$209K 0.03% 413
2020
Q3 		– Sell
-4,147
Closed -$201K – 412
2020
Q2 		$201K Buy
+4,147
New +$199K 0.03% 367

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Caprock Group's ACAD Position: Q1 2021 in Review

Caprock Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 4,207 shares — an estimated $225K sold.

Caprock Group first reported a position in ACAD in Q2 2020 and held it in 2 quarters. The position peaked at $225K in Q4 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

  • Caprock Group reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Caprock Group sold 4,207 Acadia Pharmaceuticals shares in Q1 2021, an estimated $225K.
  • Caprock Group first reported a position in Acadia Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Caprock Group's Acadia Pharmaceuticals position peaked at $225K in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Caprock Group's 13F filing for Q1 2021, filed 29 Apr 2021.